Biotech Values

[DewDiligence]

Re: GTCB and Scancell Collaborate on SC101 Antibody

It’s nice to have another potential partner. However, from the wording of today’s PR (“Their agreement contemplates that both companies will work toward the establishment of a definitive agreement for the potential clinical development of SC101”), I think we can infer that cash expenditures by GTCB at this stage of the project will be de minimus.